When faced with a patient having lash or eyebrow hair loss, a careful history searching for clues is help-ful. Hair loss involving the eyelashes or eye-brow area may result from several conditions including skin diseases, drug side effects, endocrine abnormalities, metabolic abnormalities, inflammation, toxins, radiation effects, systemic diseases, infection, and trauma.
The acute onset of a red, painful, proptotic eye will almost always cause the emergency room or primary-care physician to elicit an immediate ophthalmic consultation for the possibility of orbital cellulitis or orbital mass. In the absence of systemic infection or sinusitis, however, orbital inflammatory pseudotumor is more likely to be the diagnosis.
Ophthalmologists prescribing timolol hemihydrate (Betimol, Santen Pharmaceuticals) can be assured their patients are receiving a brand-name nonselective beta-blocker product that is safe, effective, and economical, said Michael S. Berlin, MD, and George A. Cioffi, MD.
Galveston, TX-Three-times-a-day treatment with famciclovir (Famvir, Novartis) was as effective against ophthalmic herpes zoster as five-times-a-day acyclovir (Zovirax, Glaxo Wellcome) in a major international trial, said Stephen K. Tyring, MD, PhD.
Editor's Note: James A. Davison, MD, is associate clinical professor, department of ophthalmology, University of Utah, Salt Lake City. His practice is the Wolfe Clinic, Marshalltown, IA. He discusses his cataract technique with Ophthalmology Times Senior Editor Julia Talsma.
Studies show potential problems, but many questions remain unanswered
Editor's Note: Randall J. Olson, MD, is the John A. Moran presidential professor and chair of ophthalmology, and director of the John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City. He recently spoke with Ophthalmology Times on his approach to cataract surgery.
Blepharospasm is a condition of uncontrolled squeezing of the eyelid protractors (orbicularis oculi, corrugator supercilii, and procerus). Untreated, the disease can vary from being a mere annoyance to complete visual disability.
Irvine, CA-When David E.I. Pyott became president and CEO of Allergan Inc. in January 1998, the company was evaluating its position in the eye-care market.
Epithelial ingrowth is the migration of epithelial cells from outside the flap-bed interface into the interface postoperatively. Epithelial implantation is the placement of epithelial cells into the interface during the procedure. The incidence of epithelial ingrowth and implantation has been reported as high as 10%, although it can be as low as 0.2%1 to 0.4%2 if meticulous surgical technique is employed.